EMA Withdrawn: Clopidogrel BMS (clopidogrel (as hydrogen sulfate)) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA information indicates that the clopidogrel BMS product (clopidogrel as hydrogen sulfate) has been withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• Clopidogrel BMS (clopidogrel as hydrogen sulfate) (clopidogrel hydrogen sulfate)

Snippet

Status: Withdrawn. Therapeutic area: Stroke;Peripheral Vascular Diseases;Myocardial Infarction;Acute Coronary Syndrome. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 26/10/2009